Sanofi SA Inhaber EO 2

FSNW

(FSE)

€ 68,69 <%= Resources.Global.txtUp %>

Opdateret 22-06-2018

Ændring %	1,58%
Ændring	1,07
Volume	932
Høj	€ 68,87
Lav	€ 66,80
Åben	€ 66,80
ISIN	FR0000120578
Seneste luk	€ 67,62
# af aktier	1.249,02M
Markedsværdi	85.795M EUR

I dag

Market closed

Markedet er lukket, åbner klokken 09:00


Kursudvikling	Seneste	1 uge	1 måned	3 mdr	6 mdr	1 år

	68,69	-0,2%	4,1%	7,5%	-5,3%	-22,0%

Dansk
Engelsk
Fondsbørsmeddelelser

	19 jun	Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

	19 jun	Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

	19 jun	Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure

	19 jun	Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure

	18 jun	Sanofi: Disclosure of trading in own shares

	13 jun	Sanofi : Sanofi successfully prices USD 2 billion bond issue

	13 jun	Sanofi : Sanofi successfully prices USD 2 billion bond issue

	12 jun	Information concerning the total number of voting rights and shares

	11 jun	Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan

	11 jun	Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan

Flere nyheder

	Seneste	1 uge	1 måned	3 mdr	6 mdr	1 år	ÅTD

Konkurrenter

Abbott Laboratories	61,94	-1,5%	0,2%	4,1%	8,8%	26,2%	8,5%

Bristol-Myers Squibb Company	55,14	0,6%	5,0%	-11,2%	-9,5%	-2,6%	-10,0%

Eli Lilly and Company	85,92	-1,1%	3,9%	14,9%	1,0%	2,4%	1,7%

Merck & Company Inc (new)	61,47	-0,9%	3,9%	15,1%	9,1%	-7,1%	9,2%

Pfizer Inc	36,51	0,4%	1,5%	5,9%	1,0%	6,8%	0,8%

Astrazeneca PLC ORD SHS $0.25	5.215,00	-3,4%	-4,4%	8,9%	5,5%	-3,4%	1,8%

Novartis NAM SF 0,50	64,90	-0,6%	-0,8%	0,8%	-7,3%	-15,7%	-8,1%

Roche Hldg AG GEN	188,04	4,5%	0,6%	1,6%	-10,4%	-19,4%	-10,7%

Glaxosmithkline PLC ORD 25P	1.530,23	-1,7%	1,5%	16,3%	17,5%	-10,4%	15,7%

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just over 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales.

Instrumenter	Kurs	Ændring
Abbott Labor..	61,94	0,3%
Bristol-Myer..	55,14	2,2%
Eli Lilly an..	85,92	-0,2%
Merck & Comp..	61,47	0,5%
Pfizer Inc	36,51	0,6%
Astrazeneca ..	5.215,00	-0,8%
Novartis NAM..	64,90	1,7%
Roche Hldg A..	188,04	0,5%
Glaxosmithkl..	1.530,23	-0,5%

Følg os:

Facebook

Twitter

Copyright Euroinvestor A/S 2018 Disclaimer | Cookie- og privatlivspolitik | Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.

23. juni 2018 02:42:29
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris

Sanofi SA Inhaber EO 2

Nyheder om Sanofi SA Inhaber EO 2

Relaterede

Sanofi SA Inhaber EO 2

Nyheder om Sanofi SA Inhaber EO 2

Relaterede

Firmaprofil

Peers